Shandong Loncom Pharmaceutical Co., Ltd. has achieved a major regulatory milestone by obtaining the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Sorafenib Tosylate active pharmaceutical ingredient (API). This accomplishment h
Psoriasis is a long-term, chronic autoimmune disease that affects the skin, causing red, scaly patches, itching, and discomfort. For many patients, it is more than a skin condition—it also impacts emotional well-being and daily life.
Apremilast is a modern pharmaceutical compound that has become a critical player in the treatment of autoimmune and inflammatory conditions. It is primarily used to manage diseases such as psoriasis, psoriatic arthritis, and Behçet’s disease, which are chronic and often severely impact a person’s quality of life.
The treatment of hormone-dependent conditions such as uterine fibroids and endometriosis has long been a challenge for women worldwide. Traditional therapies, including hormonal treatments and surgical interventions, often come with significant side effects or invasive procedures that can affect the quality of life.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
